MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
2.195
-0.035 (-1.57%)
Nov 21, 2024, 10:52 AM EST - Market open
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2023. The number of employees decreased by 5 or -27.78% compared to the previous year.
Employees
13
Change (1Y)
-5
Growth (1Y)
-27.78%
Revenue / Employee
n/a
Profits / Employee
-$1,995,337
Market Cap
52.61M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13 | -5 | -27.78% |
Dec 31, 2022 | 18 | 9 | 100.00% |
Dec 31, 2021 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Singular Genomics Systems | 255 |
Vor Biopharma | 168 |
DBV Technologies | 105 |
X4 Pharmaceuticals | 93 |
Aadi Bioscience | 89 |
Owlet | 76 |
IO Biotech | 68 |
Kezar Life Sciences | 58 |
MAIA News
- 14 days ago - MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - Business Wire
- 16 days ago - MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Business Wire
- 23 days ago - MAIA Biotechnology Announces $2.44 Million Private Placement - Business Wire
- 5 weeks ago - MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics - Business Wire
- 2 months ago - MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 4 months ago - MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients - Benzinga
- 4 months ago - MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent - Business Wire